Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Income from Continuing Operations (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Income from Continuing Operations data on record, last reported at 65249000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 33.13% year-over-year to 65249000.0; the TTM value through Dec 2025 reached 263497000.0, down 59.62%, while the annual FY2025 figure was 263497000.0, 59.62% down from the prior year.
  • Income from Continuing Operations reached 65249000.0 in Q4 2025 per OCUL's latest filing, up from 67971000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 19498000.0 in Q1 2022 and bottomed at 67971000.0 in Q3 2025.
  • Average Income from Continuing Operations over 5 years is 34392950.0, with a median of 22898000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: grew 10.95% in 2022, then crashed 115.52% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 19723000.0 in 2021, then dropped by 5.38% to 20784000.0 in 2022, then dropped by 9.42% to 22741000.0 in 2023, then plummeted by 115.52% to 49011000.0 in 2024, then tumbled by 33.13% to 65249000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 65249000.0 in Q4 2025, 67971000.0 in Q3 2025, and 67202000.0 in Q2 2025.